Indirubin

• UNSPSC Description:

  Indirubin (Couroupitine B) is a bis-indole alkaloid and has emarkable anticancer activity against chronic myelocytic leukemia[1][2].

• Target Antigen:

  Apoptosis

• Type:

  Natural Products

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Indirubin.html

• Purity:

  98.74

• Solubility:

  DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C1NC2=C(C=CC=C2)/C1=C3NC4=C(C=CC=C4)C\3=O

• Molecular Weight:

  262.26

• References & Citations:

  [1]Kim MH, et al. Indirubin, a purple 3,2- bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model. J Ethnopharmacol. 2013 Jan 9;145(1):214-9.|[2]Hsieh WL, et al. Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012 Aug;67(2):140-6.|[3]Zhang X, et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer. 2011 Nov 15;129(10):2502-11.|[4]Alex D, et al. Indirubin shows anti-angiogenic activity in an in vivo zebrafish model and an in vitro HUVEC model. J Ethnopharmacol. 2010 Sep 15;131(2):242-7.|[5]Li, Zhuohong, et al. Indirubin inhibits cell proliferation, migration, invasion and angiogenesis in tumor-derived endothelial cells. OncoTargets and therapy vol. 11 2937-2944. 18 May. 2018.|[6]Mohan, Lakshmi, et al. Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine. Biomed Pharmacother. 2018 Sep;105:506-517.|[7]Wang, Qi, et al. Indirubin alleviates bleomycin-induced pulmonary fibrosis in mice by suppressing fibroblast to myofibroblast differentiation. Biomedicine pharmacotherapy vol. 131 (2020): 110715.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  479-41-4